Saltar al contenido
Merck

PZ0191

Crizotinib

≥98% (HPLC), c-Met (hepatocyte growth factor receptor) inhibitor, powder

Sinónimos:

(R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine, PF 2341066, PF-02341066, PF02341066, Xalkori

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Acerca de este artículo

Fórmula empírica (notación de Hill):
C21H22Cl2FN5O
Número CAS:
877399-52-5
Peso molecular:
450.34
UNSPSC Code:
12352200
PubChem Substance ID:
329823765
NACRES:
NA.77
MDL number:
MFCD12407409
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100

Documentos clave

Ver Toda la documentación
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

Nombre del producto

Crizotinib, ≥98% (HPLC)

SMILES string

C[C@@H](Oc1cc(cnc1N)-c2cnn(c2)C3CCNCC3)c4c(Cl)ccc(F)c4Cl

InChI

1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1

InChI key

KTEIFNKAUNYNJU-GFCCVEGCSA-N

assay

≥98% (HPLC)

form

powder

color

white to tan

storage temp.

room temp

Quality Level

100

Gene Information

human ... ALK(238), MET(4233)

Categorías relacionadas

Application

Crizotinib has been used:
  • to investigate its effects on hepatocyte growth factor receptor (c-Met) expression, proliferation and apoptosis
  • to block neurotrophic tyrosine kinase receptor type 1 (NTRK1) activity in epithelial cells
  • to restore sensitivity to erlotinib

Biochem/physiol Actions

ATP-competitive c-MET / ALK Inhibitor
Crizotinib (PF-02341066) is an ATP-competitive inhibitor of the receptor tyrosine kinases (RTKs) c-Met (hepatocyte growth factor receptor) and anaplastic lymphoma kinase (ALK). Crizotinib is a highly specific inhibitor of c-Met and ALK among > 120 different RTKs surveyed. Crizotinib was approved for treatment of a subtype of nonsmall-cell lung cancer (NSCLC) with ALK fusion mutations.

Features and Benefits

This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

signalword

Warning

Hazard Classifications

Aquatic Acute 1 - Eye Irrit. 2 - Muta. 2 - Skin Sens. 1

Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
0000489022
0000489022
0000360769
0000360769
0000187253

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Zheng Liu et al.
Oncoimmunology, 9(1), 1758003-1758003 (2020-09-15)
Despite some of the oncogenic driver mutations that have been associated with increased expression of programmed death-ligand 1 (PD-L1), the correlation between PD-L1 expression and ROS1 fusion in NSCLC cells, especially for those with Crizotinib resistance has not been fully
Nicole R Infarinato et al.
Cancer discovery, 6(1), 96-107 (2015-11-12)
Neuroblastomas harboring activating point mutations in anaplastic lymphoma kinase (ALK) are differentially sensitive to the ALK inhibitor crizotinib, with certain mutations conferring intrinsic crizotinib resistance. To overcome this clinical obstacle, our goal was to identify inhibitors with improved potency that
Registered report: Widespread potential for growth factor-driven resistance to anticancer kinase inhibitors
Greenfield E, et al.
eLife, 3, e04037-e04037 (2014)
Shota Yamamoto et al.
Radiology, 272(2), 568-576 (2014-06-03)
To present a radiogenomic computed tomographic (CT) characterization of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) (ALK+). In this HIPAA-compliant institutional review board-approved retrospective study, CT studies, ALK status, and clinical-pathologic data in 172 patients with NSCLC from
PF-2341066 combined with celecoxib promotes apoptosis and inhibits proliferation in human cholangiocarcinoma QBC939 cells
Chen C, et al.
Experimental and Therapeutic Medicine, 15(5), 4543-4549 (2018)
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico